Florbetapir (18F)

7 trials 3 recruiting VVarious

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

3 Completed trials

5 Sponsors

11 Countries

Phase III

Phase II/III

Phase II

Phase III: 3 Phase II/III: 1 Phase II: 3

Indications tested

Dementia Alzheimer's type 1

Sponsors using this IMP

Eli Lilly & Co. 2 F. Hoffmann-La Roche AG 2 Acumen Pharmaceuticals Inc. 1 Glaxosmithkline Research & Development Limited 1 Institut National De La Sante Et De La Recherche Medicale 1

All trials

7 total

CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strat… Pending

2025-523264-21-00 Phase II/III 1 country Institut National De La Sante Et De La Recherche Medicale
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Phase III 6 countries F. Hoffmann-La Roche AG
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime… Recruiting

2023-509807-34-00 Phase II 3 countries Acumen Pharmaceuticals Inc.
A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Phase III 7 countries F. Hoffmann-La Roche AG
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5) Ended

2025-522340-40-00 Phase III 2 countries Eli Lilly & Co.
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended

2023-505083-11-01 Phase II 8 countries Glaxosmithkline Research & Development Limited
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended

2023-507303-55-00 Phase II 3 countries Eli Lilly & Co.

Showing 1–7 of 7 trials

← All drugs A–Z